Navigation Links
Algeta Appoints Andrew Kay as President and Chief Executive Officer
Date:12/11/2008

lly launched oncology drugs, both globally and in the key markets, which have become major products in their class.

The Board of Directors is also pleased to announce that Dr. Thomas Ramdahl, who has served as CEO of the company since 2001, will take up the position as Executive Vice President and Chief Technology Officer (CTO). Working closely with the CEO, Dr. Ramdahl will have broad responsibility for technology issues, both for late-stage products and the early discovery pipeline.

Stein Annexstad, Chairman of Algeta, said: "Algeta's lead product Alpharadin continues to make excellent progress through clinical trials, giving us great confidence of its potential as a new treatment for advanced prostate cancer. As the Company moves into a more commercial phase of its development, we are very pleased to have been able to attract Andrew to strengthen the executive management team. We believe that his international commercial expertise and networks complement the existing skills in the company and will be of significant value to Algeta in bringing Alpharadin to market."

Mr. Kay said: "I am delighted to be joining Algeta at this crucial point in its development. Alpharadin has shown in all the clinical trials completed to date its unique potential not only in treating the painful bone metastases resulting from late-stage prostate cancer, but also providing a survival benefit for patients superior to the current gold standard. The product also has potential to be an important new treatment for other cancers that metastasise to bone. In addition, the Company has several other novel targeted cancer technologies in its pipeline and an excellent technical and clinical team, which I look forward to joining in the New Year."

About Algeta

Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing new, targeted cancer therape
'/>"/>

SOURCE Algeta ASA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY) is to present important ... patients with metastatic renal cancer at the ASCO Genitourinary ... The data will be presented by Dr. Sumanta ... Center in California in his ... Ferritin and IL-8 as two baseline biomarkers that correlate ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Cytokinetics, Incorporated ... on February 28 with patients and health care advocates ... for Rare Disease Day®. Rare Disease Day is ... calling attention to the special challenges faced by patients ... , “Cytokinetics is proud to stand alongside patients and ...
(Date:2/26/2015)... S&P Capital IQ (MHFI) announced today that ... MabVax Therapeutics Holdings Inc . MabVax ... company focused on the development of vaccine and antibody-based ... of cancer. MabVax has discovered a pipeline of human ... generated by patients who have been immunized against targeted ...
(Date:2/26/2015)... TORONTO , Feb. 26, 2015 /PRNewswire/ - SQI ... SQIDF), a life sciences company that develops and commercializes ... reported its financial and operational results for the fiscal ... this press release are in Canadian dollars (CAD), unless ... Company continued to win new business from our existing ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... Sept. 21 Nile Therapeutics Inc., (OTC,Bulletin Board: ... cardiovascular disease, is pleased to announce the,appointments of ... Jennifer,Hodge as the Vice President of Development. ... our Chief Operating Officer,and was appointed Chief Financial ...
... of Physics Dr. Satyendra Kumar recently was honored ... Directors Award for Excellence for recognition of exceptional ... matter physics proposals. In all, seven program directors ... Arlington, Va. , The NSF Directors Award ...
... China, Sept. 20 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... it has launched its newest product, Shining ... the Shanghai and Changchun markets. Shining ...
Cached Biology Technology:Nile Therapeutics, Inc. Adds to Executive Management Team 2Nile Therapeutics, Inc. Adds to Executive Management Team 3Nile Therapeutics, Inc. Adds to Executive Management Team 4China-Biotics, Inc. Launches Shining Probiotics Protein Powder 2
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... 2013 BioNano Genomics , the developer of the Irys™ ... Fahim Amini , Ph.D. as vice president, Commercial Operations EMEA. ... System, making it possible for researchers and clinicians in ... Africa to access BioNano,s recently launched Irys platform. ...
... BioPharma, Inc. today announced that it has begun oral dosing ... ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside ... RSV infection. It is the only known nucleoside analog ... ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV ...
... uses pedometers to monitor how much people move throughout the ... a particular problem for office workers, and helping participants drop ... minutes a day, the fact that they,re sitting and not ... the day is in and of itself detrimental to their ...
Cached Biology News:BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA 2BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA 3Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection 2Study: Pedometer program helps motivate participants to sit less, move more 2
...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Fluorescence Preserving Media, 100 mL...
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
Biology Products: